Tavanta Therapeutics, a Philadelphia-based specialty pharmaceutical company, recently completed its reorganization from Druggability Technologies Holdings Ltd (Hungary).
“Completing the reorganization of key operational areas of the company and optimizing our portfolio for strong, sustained growth in the United States have been critical steps for Tavanta,” Lynne Powell, Tavanta Therapeutics CEO, said. “We have established a diverse, high-performing leadership team. Each member has enormous breadth and depth of experience, and together we look forward to bringing new therapeutic solutions to patients and building value for our stakeholders.”
Tavanta is seeking collaborative relationships for the development and commercialization of certain clinical candidates, the company said.
Tavanta has several drugs in the pipeline, including drugs for cystic fibrosis, multiple sclerosis, and other auto-immune diseases, which are in the preclinical phase; chronic anal fissures, phase two trials; tuberous sclerosis complex, in an investigator-sponsored phase two trial, and metastatic castration-resistant prostate cancer and high-risk metastatic castration-sensitive prostate cancer, in phase three planning.
The company’s business model is focused on accelerating new drug candidates. It has developed two platforms for the rapid screening, identification, and design of drug products for clinical development.
One platform improves the pharmacokinetic properties of poorly soluble pharmaceuticals, while the other platform integrates in-vitro and preclinical in-vivo testing to screen, characterize, and design new peptides and peptide conjugates.